CELZ-201 is a pioneering cell-based program in managing abnormal glucose tolerance and preventing T1D in high-risk individuals. The company has secured FDA authorization for an expanded access therapy using CELz-201. This personalized medicine approach, focusing on a single patient, demonstrates the company's dedication to innovative, tailored healthcare solutions. NASDAQ Markets has not reviewed and does not accept responsibility for the accuracy of this release.